Dissolve 20.4 g (2.0 eq) of disodium hydrogen phosphate in 100 mL of water. After the system is clear, add 160 mL of dichloromethane and N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanine (20.0 g, 1.0 eq), and stir at room temperature. Dissolve 8.4 g (0.4 eq) of triphosgene in 40 mL of dichloromethane and add it dropwise to the reaction system at room temperature. After the addition is complete, react for 1 h, then add 0.5 mL of pyridine, stir for 1 h, and allow to stand. Separate the liquid and concentrate the organic phase under reduced pressure to obtain an oily substance, dissolve it in 16 mL of dichloromethane, and add it dropwise to 200 mL of n-heptane. Stir at 0–10 °C for 1 h to induce crystallization. Filter under reduced pressure to obtain a white solid N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanine-N-carboxylic anhydride, and dry under vacuum at 50 °C for 10 h. 20.4 g of the product is collected, with a yield of 91.6%.
Add L-proline (9.8 g, 1.3 eq), sodium hydroxide (3.4 g, 1.3 eq), 100 mL of water, and 70 mL of tetrahydrofuran to a 250 mL three-necked flask and stir to dissolve at room temperature. Cool the flask to 0–10 °C in an ice-water bath, and dropwise add a solution of N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanine-N-carboxylic anhydride (20.0 g, 1.0 eq) in 70 mL of tetrahydrofuran. After the addition is complete, maintain the temperature at 0–10 °C and continue stirring for 2 hours. Adjust the pH to 6 with hydrochloric acid, and evaporate the tetrahydrofuran under reduced pressure. The resulting aqueous solution was adjusted to pH 4.2 with hydrochloric acid, extracted with ethyl acetate (200 mL × 4), and the resulting oily substance was concentrated under reduced pressure. The solution was dissolved in 40 mL of ethyl acetate, and a 180 mL ethyl acetate solution of maleic acid (7.6 g, 1.0 eq) was added dropwise under heating at 50 °C. After the addition was complete, the reaction was continued at this temperature for 1 h, then naturally cooled to 20–30 °C, and crystallization was allowed to continue for 1 h. The product was then filtered under reduced pressure to obtain a white solid, crude enalapril maleate. The solid was washed with 40 mL of ethyl acetate, and the sample was dried under vacuum at 50 °C for 10 h. Yield: 26.1 g, 81.7%. Add 26.0 g of crude enalapril maleate and 200 mL of water to a 500 mL three-necked flask. Start stirring and heat to 65 °C. After the system is completely dissolved, continue heating for 30 min. Turn off the heating and allow it to cool naturally to room temperature. A white solid precipitates. Continue stirring in an ice-water bath (0–10 °C) for 2 h. Filter under reduced pressure. Wash the filter cake with 50 mL of water. Dry the sample under vacuum at 50 °C for 10 h to obtain 20.9 g of white solid. Yield: 80.6%. Chromatographic purity: 99.90%.
Enalapril maleate is the second angiotensin converting enzyme inhibitor to reach
the marketplace. Like captopril, the first entry in this area, enalapril is useful in
the treatment of hypertension and congestive heart failure. It has a longer effective
half-life than captopril, allowing once or twice-daily dosing, and appears to have a
somewhat lower incidence of side effects.
White to Off-White Crystalline Powder
Enalapril maleate salt is used as a long-acting ACE inhibitor and antihypertensive, used to study diabetic angiopathy in diabetic rats and inhibition of ACE in hog plasma (I50=1.2nM). ACE inhibitors disturb the enin-angiotensin- aldosterone system. Additional ACE inhibitors include: Enalapril, Enalaprilat dihydrate, Enalaprilat, and Enalapril-d5 Maleate Salt, among others.
An antihypertensive. An angiotensin-converting enzyme (ACE) inhibitor.
ChEBI: The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angioten
in-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal diseas
in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.
N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline maleic acid salt
A mixture of 3 g of L-alanyl-L-proline, 5 g of ethyl 2-oxo-4-phenyl-butanoate,
13 g of 3A molecular sieves, and 3.6 g of Raney nickel in 85 ml of ethanol is
hydrogenated at 25°C and at 40 psig of hydrogen until uptake of hydrogen
ceases. The solids are filtered, washed with 80 ml of ethanol and the filtrates
are combined. Assay by high pressure liquid chromatography shows an 87:13
ratio of diastereoisomers in favor of the desired product. Ethanol is removed
under vacuum to afford an oil which is dissolved in 60 ml of water and 20 ml
of ethyl acetate. The pH of the stirred two-phase mixture is adjusted to 8.6
with 50% NaOH. The layers are separated and the water phase is extracted
with 2x20 ml of ethyl acetate. The water phase is adjusted to pH 4.25 with
hydrochloric acid, 12 g of NaCl is dissolved in the water, and product is
extracted with 5x12 ml of ethyl acetate. The extracts are combined and dried
with Na2SO4. The desired product, N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-
L-alanyl-L-proline, is crystallized as its maleate salt by addition of 1.86 g of
maleic acid. After stirring for 4 hours, the salt is filtered, washed with ethyl
acetate and dried to afford 5.2 g of pure product, melting point 150°-151°C.
Enalapril maleate, 1-[N[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-L-proline 1 -ethyl estermaleate (Vasotec), is a long-acting ACE inhibitor. It requiresactivation by hydrolysis of its ethyl ester to form thediacid enalaprilat. Enalapril is devoid of the side effects ofrash and loss of taste seen with captopril. These side effectsare similar to those of the mercapto-containing drugpenicillamine. The absence of the thiol group in enalaprilmaleate may free it from these side effects. The half-life is11 hours.
A long-acting angiotensin-converting enzyme inhibitor.
Angiotensin converting enzyme inhibitor:HypertensionHeart failure
Veterinary Drugs and Treatments
The principle use of enalapril/enalaprilat in veterinary medicine at
present is as a vasodilator in the treatment of heart failure. Recent
studies have demonstrated that enalapril, particularly when used
in conjunction with furosemide, does improve the quality of life
in dogs with heart failure. It is not clear, however, whether it has
any significant effect on survival times. It may also be of benefit
in treating the effects associated with valvular heart disease (mitral
regurgitation) and left to right shunts. It is being explored as
adjunctive treatment in chronic renal failure and protein losing
nephropathies.
While ACE inhibitors are a mainstay for treating hypertension in
humans, they have not been particularly useful in treating hypertension
in dogs or cats.
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect.Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDsAntihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.Bee venom extract: possible severe anaphylactoid
reactions when used togetherCiclosporin: increased risk of hyperkalaemia and
nephrotoxicity.Cytotoxics: increased risk of angioedema with
everolimus.Diuretics: enhanced hypotensive effect;hyperkalaemia with potassium-sparing diureticsESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.Gold: flushing and hypotension with sodium
aurothiomalate.Lithium: reduced excretion, possibility of enhanced
lithium toxicity.Potassium salts: increased risk of hyperkalaemiaTacrolimus: increased risk of hyperkalaemia and
nephrotoxicity.
Following absorption, oral enalapril is rapidly and
extensively hydrolysed to enalaprilat, a potent angiotensin
converting enzyme inhibitor. Peak serum concentrations
of enalaprilat occur about 4 hours after an oral dose of
enalapril tablet, and the effective half-life is 11 hours.
Excretion of enalaprilat is primarily renal. The principal
components in urine are enalaprilat, accounting for about
40% of the dose, and intact enalapril.
